• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Scilex seeks EU nod for ZTlido lidocaine patch

November 14, 2017 By Sarah Faulkner

Scilex PharmaceuticalsSorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that it filed a marketing authorization application seeking approval for its ZTlido lidocaine patch.

The San Diego, Calif.-based company said it is pursuing a hybrid regulatory pathway with the Medicines and Healthcare Products Regulatory Agency in the U.K., which will serve as the lead review agency. The company also plans to file for review in other countries, including Germany, France, Spain, Italy and Ireland.

Scilex said it expects to hear back about its marketing authorization application in the fourth quarter of 2018, since the review time is 210 days. The company is also reviewing commercial options and potential partnerships for its launch in the E.U., according to Scilex.

In September, Scilex said that the FDA received the resubmitted version of a new drug application for ZTlido. The FDA is slated to finish reviewing the company’s NDA by February 28th next year.

If the product wins approval by the FDA, the company has said it could be ready for its U.S. commercial launch in 2018. Sorrento also reportedly plans to submit a marketing authorization application for ZTlido in Europe in the fourth quarter of this year.

Sorrento’s anhydrous patch, designed for the relief of pain associated with post-herpetic neuralgia, contains just 36 milligrams of lidocaine, compared to reference products Lidoderm and Versatis, which each have 700 milligrams of the painkiller.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Scilex Pharmaceuticals, Sorrento Therapeutics

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Reader Interactions

Comments

  1. El says

    January 31, 2019 at 2:00 pm

    As a sufferer of Post herpetic neuralgia after shingles; i tried ZTLido. The information said it was designed specifically for after shingles sufferers. Well it did not work. I have been reading all the info put out by the ZTLido, one thing I noticed they tout how effective the adhesion is.!!!!
    Well I trade effective adhesion for effective treatment of pain. Besides not working, it costs a lot of money!!
    Go back to the drawing board.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS